RSV

The CDC advisory committee also endorsed GSK's pentavalent meningococcal vaccine.

AAAAI 2025: RSV vaccine and immunoprophylaxis uptake remained low in 2024 across infants, pregnant individuals, and older adults.

Your daily dose of the clinical news you may have missed.

Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.

The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

The world's first maternal vaccine against RSV in neonates and infants was approved in August. This brief slide show highlights the clinical trials that made history.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.